| Primary |
| Herpes Zoster |
20.2% |
| Product Used For Unknown Indication |
16.2% |
| Genital Herpes |
14.9% |
| Herpes Virus Infection |
8.6% |
| Cytomegalovirus Infection |
6.0% |
| Herpes Simplex |
5.6% |
| Oral Herpes |
5.6% |
| Prophylaxis |
5.0% |
| Drug Use For Unknown Indication |
3.0% |
| Pain |
2.3% |
| Back Pain |
2.0% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Anti-glomerular Basement Membrane Antibody |
1.3% |
| Cardiogenic Shock |
1.3% |
| Encephalitis Herpes |
1.3% |
| Antiviral Prophylaxis |
1.0% |
| Atrial Fibrillation |
1.0% |
| Glioblastoma Multiforme |
1.0% |
| Herpes Ophthalmic |
1.0% |
| Hiv Infection |
1.0% |
|
| Drug Ineffective |
28.2% |
| Product Substitution Issue |
13.7% |
| Neutropenia |
5.3% |
| Viral Load Increased |
4.6% |
| Vomiting |
4.6% |
| Headache |
3.8% |
| Herpes Virus Infection |
3.8% |
| Overdose |
3.8% |
| Renal Failure Acute |
3.8% |
| Foetal Exposure During Pregnancy |
3.1% |
| Ill-defined Disorder |
3.1% |
| Sensory Disturbance |
3.1% |
| Therapeutic Response Decreased |
3.1% |
| Alopecia |
2.3% |
| Arthralgia |
2.3% |
| Drug Exposure During Pregnancy |
2.3% |
| Hallucination |
2.3% |
| Heart Rate Increased |
2.3% |
| Herpes Zoster |
2.3% |
| Impaired Work Ability |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
34.6% |
| Drug Use For Unknown Indication |
11.7% |
| Herpes Zoster |
8.5% |
| Hiv Infection |
7.0% |
| Genital Herpes |
5.4% |
| Prophylaxis |
4.6% |
| Diffuse Large B-cell Lymphoma |
3.0% |
| B-cell Unclassifiable Lymphoma Low Grade |
2.8% |
| Chronic Lymphocytic Leukaemia |
2.6% |
| Mycobacterium Avium Complex Infection |
2.0% |
| T-cell Lymphoma |
2.0% |
| Antiviral Prophylaxis |
1.8% |
| B-cell Lymphoma |
1.8% |
| Hypertension |
1.8% |
| Infection Prophylaxis |
1.8% |
| Non-hodgkin's Lymphoma |
1.8% |
| Prophylaxis Against Transplant Rejection |
1.8% |
| Waldenstrom's Macroglobulinaemia |
1.8% |
| Acute Myeloid Leukaemia |
1.6% |
| Herpes Virus Infection |
1.4% |
|
| Completed Suicide |
9.7% |
| Toxicity To Various Agents |
8.1% |
| Renal Failure Acute |
6.5% |
| Thrombocytopenia |
6.5% |
| Tubulointerstitial Nephritis |
6.5% |
| Vomiting |
6.5% |
| White Blood Cell Count Decreased |
6.5% |
| Cytomegalovirus Colitis |
4.8% |
| Drug Ineffective |
4.8% |
| Neutropenia |
4.8% |
| Renal Failure |
4.8% |
| Toxic Epidermal Necrolysis |
4.8% |
| Asthenia |
3.2% |
| Blood Creatinine Increased |
3.2% |
| Condition Aggravated |
3.2% |
| Dermatitis Allergic |
3.2% |
| Dystonia |
3.2% |
| Erythema Infectiosum |
3.2% |
| Headache |
3.2% |
| Hepatitis Toxic |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.1% |
| Drug Use For Unknown Indication |
19.5% |
| Multiple Myeloma |
7.0% |
| Prophylaxis |
7.0% |
| Hiv Infection |
6.0% |
| Diffuse Large B-cell Lymphoma |
4.8% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Hypertension |
3.3% |
| Chronic Lymphocytic Leukaemia |
2.8% |
| Acute Myeloid Leukaemia |
2.8% |
| Pain |
2.6% |
| Infection Prophylaxis |
2.3% |
| Crohn's Disease |
1.9% |
| Herpes Zoster |
1.8% |
| Premedication |
1.8% |
| B-cell Lymphoma |
1.7% |
| Rheumatoid Arthritis |
1.6% |
| Mantle Cell Lymphoma |
1.5% |
| Renal Transplant |
1.4% |
| Depression |
1.3% |
|
| Thrombocytopenia |
11.1% |
| Vomiting |
10.4% |
| Pulmonary Embolism |
7.1% |
| Pyrexia |
7.1% |
| Death |
5.4% |
| Febrile Neutropenia |
5.4% |
| Pneumonia |
5.1% |
| Renal Failure |
5.1% |
| White Blood Cell Count Decreased |
5.1% |
| Renal Failure Acute |
4.7% |
| Tumour Lysis Syndrome |
4.4% |
| Septic Shock |
4.0% |
| Tubulointerstitial Nephritis |
3.7% |
| Osteonecrosis |
3.4% |
| Urinary Tract Infection |
3.4% |
| Vision Blurred |
3.4% |
| Nausea |
3.0% |
| Rash |
3.0% |
| Sepsis |
2.7% |
| Weight Decreased |
2.7% |
|
| Interacting |
| Product Used For Unknown Indication |
81.8% |
| Atrial Fibrillation |
9.1% |
| Herpes Virus Infection |
9.1% |
|
| Unresponsive To Stimuli |
66.7% |
| General Physical Health Deterioration |
33.3% |
|
